News
California start-up raises US$20m to invest in behavioural science platform
Wellth uses the science of behavioural economics to help people establish new healthy habits and improve their wellbeing
A California digital health company has secured US$20m to fund its behavioural science-based platform.
Wellth uses behavioural economics to help people to prioritise their health and build long-lasting healthy behaviours.
The platform utilises the principles of loss aversion, present bias, the intent-behaviour gap, and the endowment effect to create motivation, behaviour change and address the obstacles that prevent people with chronic conditions from improving their lifestyle.
Many individuals struggle with building lasting healthy habits, with data showing that this could take a costly toll on individuals’ health and the healthcare system.
Meanwhile, many patients struggle with medication adherence, which can negatively impact individual health outcomes, and contributes to more than US$500b in avoidable healthcare costs.
“Wellth has solved one of the hardest and most fundamental challenges in healthcare—motivating patients to take action and do what’s best for their health,” says Yuanling Yuan of SignalFire, who leads the firm’s healthcare investment strategy.
As part of the company’s programme, patients are asked to snap a daily photo of their medications, glucose levels or other healthy behaviours.
Through this daily interaction, Wellth argues, behaviours are trained into habits, which ultimately lead to lasting change and positive health outcomes.
“At the core, we’re removing barriers and giving patients the motivation to do what’s best for their health,” says Matt Loper, Wellth co-founder and CEO.
“This mission is very personal to me, since I saw my own uncle struggle with behavioural change after a type two diabetes diagnosis.
“After he passed, I set out on a personal quest to understand why humans don’t do what we’re ‘supposed to do’ when it comes to our health.”
Wellth’s most recent round, led by SignalFire, is hoped to enable Loper and his team to expand and further invest in the behavioural science engine behind the app.
Frank Williams, Wellth’s board chairman, says: “Wellth is uniquely positioned as the leading behaviour change company in healthcare.
“The team has taken an innovative approach through a data-driven, behavioural economics lens to effectively activate, engage and drive lasting impact for patients struggling to manage their health.
“This core competency can be applied to drive vastly improved health outcomes and significantly lower medical costs. As a result, the company has driven impressive growth through relationships with the nation’s leading health plan and provider-based organisations.”
Insight
Topical HRT protects bone density in women with period loss – study
Transdermal HRT best protects bone density in women with functional hypothalamic amenorrhoea, a condition that stops periods, a review of trials has found.
The meta-analysis pooled randomised clinical trials involving 692 participants and found transdermal hormone replacement therapy and teriparatide increased bone mineral density by between 2 and 13 per cent.
Functional hypothalamic amenorrhoea can follow anorexia or intense exercise. Bone mineral density measures bone strength and the amount of mineral in bone.
Around half of women with the condition have low bone mineral density, compared with about 1 per cent of healthy women, and their fracture risk is up to seven times higher.
The research was conducted by scientists at Imperial College London and Imperial College Healthcare NHS Trust.
Professor Alexander Comninos, senior author of the study and consultant endocrinologist at the trust, said: “Bone density is lost very rapidly in FHA and so addressing bone health early is very important to reduce the lifelong risk of fractures.
“Our study provides much needed comparisons of all the available treatments from all available studies.
“Clearly the best treatment is to restore normal menstrual cycles and therefore oestrogen levels through various psychological, nutritional or exercise interventions – but that is not always possible.
“The foundation for bone health is good calcium and vitamin D intake (through diet and/or supplements) but we have additional treatments that are more effective.”
When FHA is diagnosed, clinicians first try to restore periods through lifestyle measures, including psychological and dietary support, but these can fail. Guidelines then recommend giving oestrogen, though the best form was unclear.
The team reviewed all prior randomised trials comparing therapies, including oral and transdermal oestrogen, and also assessed teriparatide, a prescription bone-building drug used for severe osteoporosis.
They found no significant benefit for oral contraceptive pills or oral hormone therapy.
A recent UK audit reported that about a quarter of women with anorexia-related FHA are prescribed the oral contraceptive pill for bone loss; the study suggests using transdermal therapy instead.
Comninos said: “Our goal is simple: to help women receive the right treatment sooner and to protect their bone health in the long-term.
“We hope this study provides clinicians with better evidence to choose transdermal oestrogen when prescribing oestrogen and so inform future practice guidelines.
“Right now, millions of women with FHA may not be receiving the best treatments for their bone health.”
Insight
AI cuts interval breast cancers in Swedish trial
Mental health
Fear of ageing may age women faster, study suggests
-
Features4 weeks agoWomen’s health enters a new era – the trends shaping femtech in 2026
-
Insight4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Features4 weeks agoBest menopause apps and products for 2026
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoHigher maternal blood pressure increases risk of pregnancy complications, study finds
-
Entrepreneur4 weeks agoXella Health closes US$3.7 million in pre-seed financing
-
Events4 weeks agoInside the first wave of speakers confirmed for Women’s Health Week USA 2026






